H
Hrain biotechnology
Hrain biotechnology is adhering to the concept of treating diseases and saving people
About Hrain biotechnology
Based in Shanghai's Zhangjiang Hi-Tech Park, Hrain Biotechnology is a biopharmaceutical firm established in 2015, concentrating on the development and production of advanced immune cell therapies for cancer. The company was founded by a team of internationally recognized scientists, with Li Guoshun serving as the legal representative and chairman. Mr. Li obtained a degree in economic management from Xiamen University in 1996.
Hrain Biotechnology's core focus is on developing tumor immunotherapy technologies to offer precise treatment solutions for cancer patients. The company’s research and development strategy centers on Chimeric Antigen Receptor T-cell (CAR-T) technology, while also advancing other platforms such as CAR-Natural Killer (CAR-NK) and T-cell receptor (TCR-T) therapies. This approach has resulted in a varied pipeline of products at different stages, from early research to mature clinical trials, targeting both hematological malignancies and solid tumors. The company's business model involves in-house research and development, conducting clinical trials in collaboration with multiple hospitals in cities like Beijing and Shanghai, and ultimately, the production and commercialization of these cell therapies.
The firm's leading technology, CAR-T cell therapy, is a gene engineering process that modifies a patient's own T cells to recognize and attack cancer cells. Another key area is CAR-NK cell therapy, which similarly engineers NK cells to target tumors. Hrain has received investigational new drug (IND) approval for several of its CAR-T products, including a treatment for advanced/metastatic renal cancer. The company has successfully raised significant capital to fund its operations, including a Series B round of $28 million and a total of over $156 million in funding from various investors like Shenzhen Capital Group, Qiming Venture Partners, and Yingke Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Huangpu, China
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 33.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2021 | $0 | — | Yingke Capital | ↗ |
| SERIES BOther financing | Sep 2020 | $28M | $110M | Spinnotec · New China Fund | ↗ |
Growth signals
Latest recorded traffic for Hrain biotechnology is 1.4K monthly website visits, up 775% over the last three months. Hrain biotechnology's team declined 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hrain biotechnology in the Huangpu ecosystem
The Hrain biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Shenzhen Capital Group
Spinnotec- NFNew China Fund
Series B and later1 investor entered at this stage
Yingke Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hrain biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hrain biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









